MeSH term
Frequency | Condition_Probility | Aged | 23 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Female | 65 | 0.0 |
Humans | 251 | 0.0 |
Animals | 111 | 0.0 |
Animals, Genetically Modified | 7 | 2.0 |
Antigens, CD55/*genetics | 5 | 71.0 |
Embryo Transfer | 2 | 2.0 |
Swine | 22 | 1.0 |
Antigens, CD55/immunology | 5 | 38.0 |
Antigens, CD59/immunology | 4 | 40.0 |
Cell Culture Techniques | 3 | 0.0 |
*Complement Activation | 18 | 4.0 |
Complement Membrane Attack Complex/immunology | 2 | 20.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 171 | 0.0 |
Tumor Cells, Cultured | 15 | 0.0 |
Antigens, CD55/*metabolism | 14 | 46.0 |
Binding Sites | 10 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
HT29 Cells | 2 | 1.0 |
Mutation | 6 | 0.0 |
Receptors, Virus/*metabolism | 3 | 3.0 |
Vero Cells | 2 | 0.0 |
Antigens, CD/metabolism | 6 | 0.0 |
Antigens, CD55/metabolism | 8 | 25.0 |
Antigens, CD59/metabolism | 5 | 15.0 |
Cell Differentiation | 3 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Complement Inactivators/*metabolism | 11 | 31.0 |
Membrane Glycoproteins/metabolism | 6 | 1.0 |
Microscopy, Immunoelectron | 7 | 1.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Graft Rejection/*prevention & control | 3 | 7.0 |
*Heart Transplantation | 2 | 2.0 |
Macaca mulatta | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 66 | 0.0 |
*Transplantation, Heterologous | 5 | 7.0 |
Cells, Cultured | 23 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Up-Regulation | 6 | 0.0 |
Antigens, CD/*genetics | 7 | 2.0 |
Blotting, Western | 15 | 0.0 |
Cytokines/pharmacology | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Flow Cytometry | 29 | 0.0 |
Immunohistochemistry | 15 | 0.0 |
Male | 55 | 0.0 |
Membrane Glycoproteins/*genetics | 8 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Swine/*genetics | 2 | 1.0 |
Heart Transplantation/*immunology | 2 | 3.0 |
Mice | 35 | 0.0 |
Cell Line | 31 | 0.0 |
Comparative Study | 28 | 0.0 |
Complement Activation/genetics | 2 | 25.0 |
Complement Inactivators/biosynthesis/genetics/*physiology | 2 | 100.0 |
K562 Cells | 2 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Transfection | 23 | 0.0 |
3T3 Cells | 3 | 0.0 |
Antigens, CD/genetics/*metabolism | 2 | 2.0 |
Antigens, CD55/genetics/*metabolism | 5 | 62.0 |
Complement/*immunology | 13 | 9.0 |
Complement Inactivators/physiology | 3 | 42.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
Guinea Pigs | 13 | 1.0 |
Membrane Glycoproteins/genetics/*metabolism | 2 | 1.0 |
Plasmids/genetics | 2 | 0.0 |
Rabbits | 16 | 0.0 |
Species Specificity | 7 | 0.0 |
Transplantation, Heterologous | 6 | 0.0 |
Models, Molecular | 6 | 0.0 |
Protein Structure, Tertiary | 8 | 0.0 |
Receptors, Complement/*metabolism | 2 | 1.0 |
Antibodies, Monoclonal/immunology | 12 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Antigens, CD55/genetics/immunology/*metabolism | 3 | 100.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Erythrocytes/immunology | 9 | 3.0 |
Mice, Knockout | 4 | 0.0 |
Spermatozoa/immunology | 3 | 16.0 |
Hamsters | 23 | 0.0 |
Hela Cells | 6 | 0.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Cloning, Molecular | 8 | 0.0 |
Complement | 4 | 8.0 |
Protein Binding | 7 | 0.0 |
Protein Conformation | 8 | 0.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Base Sequence | 23 | 0.0 |
Complement Activation | 14 | 4.0 |
Gene Expression | 8 | 0.0 |
Glycosylphosphatidylinositols/metabolism | 4 | 7.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Adenocarcinoma/*metabolism/pathology | 2 | 1.0 |
Antigens, CD55/*biosynthesis | 2 | 28.0 |
Neoplasm Staging | 2 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Middle Aged | 34 | 0.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Child | 4 | 0.0 |
Time Factors | 3 | 0.0 |
Complement/*metabolism | 9 | 5.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Models, Animal | 2 | 0.0 |
Rats | 13 | 0.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Receptors, Complement 3b/metabolism | 2 | 9.0 |
Antigens, CD55/*genetics/immunology | 3 | 42.0 |
*Gene Transfer Techniques | 3 | 0.0 |
Immunoblotting | 8 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Antigens, CD/*metabolism | 12 | 1.0 |
CHO Cells | 16 | 0.0 |
Complement 3b/metabolism | 3 | 2.0 |
Complement Pathway, Alternative | 5 | 4.0 |
Complement Pathway, Classical | 4 | 3.0 |
Consensus Sequence | 3 | 0.0 |
Membrane Glycoproteins/*metabolism | 11 | 2.0 |
Antigens, CD59/*metabolism | 7 | 19.0 |
Adult | 35 | 0.0 |
Blotting, Northern | 8 | 0.0 |
Molecular Weight | 7 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Receptors, Virus/metabolism | 2 | 3.0 |
*Antigens, CD | 8 | 1.0 |
Antigens, CD55 | 101 | 53.0 |
Antigens, CD59 | 30 | 15.0 |
Receptors, Complement 3b | 11 | 3.0 |
*Animals, Genetically Modified | 3 | 27.0 |
*Gene Expression Regulation | 3 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Complement Activation/*genetics | 2 | 28.0 |
*Multigene Family | 3 | 0.0 |
Sequence Alignment | 9 | 0.0 |
Antigens, CD55/biosynthesis/*genetics | 2 | 66.0 |
Complement Inactivators/*genetics | 2 | 16.0 |
DNA Primers/chemistry | 3 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Complement/physiology | 3 | 6.0 |
Adenoviridae | 2 | 2.0 |
Antigens, CD55/genetics/*physiology | 6 | 66.0 |
Antigens, CD59/genetics/*physiology | 4 | 50.0 |
Complement 3/analysis | 2 | 0.0 |
Complement Inactivators/*physiology | 7 | 35.0 |
Endothelium, Vascular/physiology | 2 | 3.0 |
Genetic Vectors | 7 | 0.0 |
Membrane Glycoproteins/genetics/*physiology | 2 | 2.0 |
Perfusion | 5 | 2.0 |
Transplantation, Heterologous/*immunology | 5 | 8.0 |
Alternative Splicing | 2 | 0.0 |
Amino Acid Sequence | 33 | 0.0 |
Complement 3 | 2 | 5.0 |
Molecular Sequence Data | 42 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Evolution | 3 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Transgenes | 2 | 0.0 |
Immunoenzyme Techniques | 9 | 0.0 |
Testis/immunology | 2 | 14.0 |
Adolescent | 8 | 0.0 |
Reference Values | 6 | 0.0 |
Epithelium/immunology | 7 | 5.0 |
Cytotoxicity, Immunologic | 7 | 0.0 |
Models, Biological | 2 | 0.0 |
Complement/*physiology | 12 | 13.0 |
Enzyme Activation | 2 | 0.0 |
*Hemolysis/drug effects | 2 | 33.0 |
In Vitro | 10 | 0.0 |
U937 Cells | 2 | 0.0 |
Cell Membrane/immunology | 3 | 1.0 |
Membrane Glycoproteins/*genetics/metabolism | 2 | 2.0 |
Antigens, CD55/*genetics/metabolism | 2 | 100.0 |
Fluorescent Antibody Technique | 15 | 0.0 |
Glycosylation | 6 | 0.0 |
Precipitin Tests | 6 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Trypsin | 3 | 1.0 |
Biosensing Techniques | 2 | 3.0 |
Hemagglutination | 3 | 8.0 |
Hemagglutination Inhibition Tests | 2 | 4.0 |
Neutralization Tests | 2 | 0.0 |
Phenotype | 9 | 0.0 |
Antibodies/metabolism | 3 | 3.0 |
Endothelium/metabolism | 2 | 3.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Brain/*metabolism | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Complement Inactivators | 3 | 15.0 |
Complement 3/metabolism | 9 | 3.0 |
Complement Factor I/metabolism | 2 | 22.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
Antibodies, Monoclonal/biosynthesis | 2 | 7.0 |
Chromatography, Affinity | 3 | 0.0 |
Mice, Inbred BALB C | 8 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Complement 3/*metabolism | 4 | 2.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Blotting, Southern | 3 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Erythrocytes/*immunology | 12 | 6.0 |
Hemoglobinuria, Paroxysmal/*immunology | 5 | 22.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Antigens, CD/biosynthesis | 4 | 1.0 |
Antigens, CD55/biosynthesis | 2 | 28.0 |
Antigens, CD59/biosynthesis | 2 | 20.0 |
Complement Inactivators/*biosynthesis | 4 | 66.0 |
Membrane Glycoproteins/biosynthesis | 3 | 1.0 |
Membrane Proteins/*biosynthesis | 3 | 5.0 |
Antigens, Heterophile/immunology | 2 | 20.0 |
Antigens, CD/physiology | 3 | 1.0 |
Antigens, CD55/physiology | 2 | 50.0 |
Antigens, CD59/physiology | 2 | 28.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Receptors, Complement/physiology | 2 | 10.0 |
Adenocarcinoma/immunology | 2 | 4.0 |
Antigens, CD55/*analysis | 4 | 30.0 |
Antigens, CD59/*analysis | 3 | 16.0 |
Breast/immunology | 2 | 33.0 |
Intestinal Mucosa/immunology | 2 | 3.0 |
Lymphocytes/immunology | 4 | 1.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
Antigens, CD/immunology | 3 | 0.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 6 | 6.0 |
Blood Group Antigens/*genetics/immunology | 2 | 18.0 |
Antigens, CD/*analysis | 11 | 1.0 |
Antigens, CD55/analysis | 3 | 15.0 |
Antigens, CD59/analysis | 2 | 9.0 |
Complement Inactivators/*analysis | 10 | 34.0 |
Intestinal Mucosa/*immunology | 2 | 2.0 |
Membrane Glycoproteins/analysis | 8 | 3.0 |
Ligands | 2 | 0.0 |
Blood Group Antigens/*immunology | 3 | 9.0 |
Solubility | 3 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Exons | 2 | 0.0 |
Introns | 3 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Antigens, CD55/*immunology | 4 | 33.0 |
Arthritis, Rheumatoid/blood/*immunology | 2 | 7.0 |
English Abstract | 6 | 0.0 |
Pregnancy | 6 | 0.0 |
Cross Reactions | 3 | 0.0 |
Antibodies, Monoclonal | 12 | 0.0 |
Isoantigens/*blood | 3 | 37.0 |
Blood Transfusion | 2 | 1.0 |
Heart/*physiology | 2 | 3.0 |
Heart Function Tests | 2 | 11.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
*Models, Molecular | 2 | 1.0 |
*Peptide Mapping | 2 | 14.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
Cell Survival | 2 | 0.0 |
Complement Inactivators/metabolism | 2 | 10.0 |
Cytotoxicity, Immunologic/*immunology | 2 | 4.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Complement Inactivators/biosynthesis | 2 | 28.0 |
Complement 3 Convertase/metabolism | 6 | 15.0 |
Repetitive Sequences, Nucleic Acid | 5 | 0.0 |
Blood/*immunology | 2 | 15.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Receptors, Complement 3b/*metabolism | 2 | 10.0 |
Adsorption | 2 | 1.0 |
Antigens, CD/*biosynthesis | 3 | 1.0 |
Complement Activation/*physiology | 2 | 8.0 |
Membrane Glycoproteins/*biosynthesis | 3 | 3.0 |
Complement/*analysis | 2 | 1.0 |
Glycoproteins/analysis | 2 | 3.0 |
*Molecular Chaperones | 2 | 1.0 |
Hemolysis/*physiology | 2 | 25.0 |
Cell Division/physiology | 2 | 0.0 |
Antibodies/immunology | 3 | 0.0 |
Cattle | 3 | 0.0 |
*Complement Inactivators | 4 | 5.0 |
Receptors, Complement 3b/*analysis | 4 | 26.0 |
Antigens, Surface/immunology | 2 | 1.0 |
Complement Activation/*immunology | 2 | 3.0 |
Complement Inactivators/*immunology | 2 | 16.0 |
Chromosome Mapping | 5 | 0.0 |
DNA, Complementary/*genetics/isolation & purification | 2 | 8.0 |
Linkage (Genetics) | 4 | 0.0 |
RNA/analysis | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Complement Inactivators/analysis | 5 | 35.0 |
Flow Cytometry/methods | 2 | 0.0 |
Neutrophils/physiology | 2 | 1.0 |
Receptors, Complement/*physiology | 3 | 5.0 |
Antigens, CD/analysis | 6 | 0.0 |
Colon/immunology | 2 | 9.0 |
Kinetics | 5 | 0.0 |
Antibodies/pharmacology | 2 | 0.0 |
Erythrocyte Aging | 2 | 6.0 |
Hemolysis | 8 | 2.0 |
Receptors, Complement 3b/chemistry | 2 | 66.0 |
Conserved Sequence | 2 | 0.0 |
*Glycoproteins | 2 | 0.0 |
Mutagenesis | 3 | 0.0 |
Hemoglobinuria, Paroxysmal/*genetics | 2 | 18.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Erythrocyte Membrane/*immunology | 2 | 4.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Genes, Structural | 5 | 0.0 |
Membrane Glycoproteins/*physiology | 3 | 1.0 |
Membrane Glycoproteins/*analysis | 10 | 6.0 |
Epitope Mapping | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Endothelium, Vascular/cytology/*immunology | 2 | 6.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 2 | 3.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Virulence | 2 | 0.0 |
Antigens, Surface/analysis | 3 | 0.0 |
Cell Separation | 3 | 0.0 |
Glycosylphosphatidylinositols/*metabolism | 4 | 7.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Mammals | 2 | 0.0 |
Trypanosoma brucei brucei/*metabolism | 2 | 40.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Membrane Glycoproteins/chemistry/metabolism | 2 | 20.0 |
Peptide Mapping | 2 | 0.0 |
Trypsin/pharmacology | 2 | 1.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Trophoblasts/immunology | 4 | 12.0 |
Hemoglobinuria, Paroxysmal/blood | 2 | 28.0 |
Antigens, CD/blood | 2 | 0.0 |
Membrane Glycoproteins/blood | 2 | 6.0 |
Antigens, CD/*immunology | 3 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Membrane Glycoproteins/*immunology | 4 | 2.0 |
Spermatozoa/*immunology | 2 | 4.0 |
Membrane Proteins/analysis | 6 | 5.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Erythrocyte Membrane/metabolism | 2 | 3.0 |
Antigens, CD58 | 3 | 2.0 |
Phosphoric Diester Hydrolases/pharmacology | 2 | 13.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
Membrane Glycoproteins/analysis/*immunology | 2 | 28.0 |
Hemoglobinuria, Paroxysmal/*blood | 7 | 26.0 |
Immunophenotyping | 2 | 0.0 |
*Phenotype | 2 | 0.0 |
Blood Proteins/*genetics | 2 | 1.0 |
*Genes, Regulator | 2 | 1.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
Complement 3/*immunology | 2 | 3.0 |
Epithelium/chemistry | 2 | 1.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Granulocytes/immunology | 2 | 3.0 |
Proteins/*analysis | 2 | 1.0 |
Complement 3/immunology | 2 | 2.0 |
Pregnancy/*immunology | 3 | 5.0 |
Complement Inactivators/*pharmacology | 2 | 7.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Glycosylphosphatidylinositols | 7 | 13.0 |
Phosphatidylinositols/*blood | 2 | 20.0 |
Membrane Proteins/*deficiency | 4 | 50.0 |
Cell Survival/immunology | 2 | 3.0 |
Restriction Mapping | 3 | 0.0 |
*Complement Pathway, Alternative | 4 | 3.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Erythrocytes/parasitology | 2 | 5.0 |
Schistosomiasis mansoni/immunology/parasitology | 2 | 100.0 |
Sheep | 2 | 0.0 |
Hemoglobinuria, Paroxysmal/*pathology | 2 | 66.0 |
Ethanolamines/metabolism | 3 | 16.0 |
Membrane Proteins/*physiology | 3 | 2.0 |
*Chromosomes, Human, Pair 1 | 4 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Acetylcholinesterase/blood | 2 | 7.0 |
Cytotoxicity, Immunologic/*drug effects | 2 | 2.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Complement Inactivators/*deficiency | 3 | 60.0 |
Erythrocyte Membrane/immunology | 3 | 7.0 |
Membrane Proteins/*analysis | 3 | 4.0 |
Cell Membrane/physiology | 3 | 2.0 |
DNA/genetics | 2 | 0.0 |
Ethanolamine | 3 | 60.0 |
Glycolipids/*metabolism | 3 | 10.0 |
Phosphatidylinositols/*metabolism | 3 | 3.0 |
Phosphoric Diester Hydrolases/metabolism | 2 | 7.0 |
Complement Factor H | 4 | 5.0 |
Complement Factor I | 2 | 9.0 |
Membrane Proteins/physiology | 2 | 2.0 |
Receptors, Complement 3d | 3 | 2.0 |
Erythrocytes/analysis | 3 | 12.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
Antigens, CD55/*physiology | 2 | 66.0 |
Carbohydrate Conformation | 2 | 1.0 |
*Hemolysis | 2 | 2.0 |
Immunosorbent Techniques | 2 | 0.0 |
Cell Adhesion | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Complement 3b/immunology | 2 | 5.0 |
Complement 4b | 2 | 2.0 |
Macrophage-1 Antigen | 2 | 4.0 |
Complement Membrane Attack Complex | 3 | 3.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
